Opinion: Rich Guys With Causes Lack Accountability
By David Wessel,
Wall Street Journal
| 01. 20. 2005
The story of the rich man who goes into politics and spends his money to get elected is old and familiar. Once he gets into office, though, he can't do much without enlisting Congress or a state legislature.
And then there is California, that font of innovation. In the latest twist in direct democracy, a rich man with a cause proposes a ballot initiative to spend taxpayer money on something the gridlocked state legislature won't back. He puts a lot of his own money into a successful campaign. When it passes, he takes charge of spending the money.
Robert N. Klein II is a Palo Alto real-estate developer whose son has juvenile diabetes. He chipped in about $3 million (of the $25 million total) for the campaign he led to get voters to OK borrowing $3 billion to finance stem-cell research. The constitutional amendment and accompanying statute won with 59% of the vote.
see moreThis is the latest manifestation of a California tradition of voters deciding for themselves how to spend tax money. In 2002, then-actor Arnold Schwarzenegger led a drive...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Charles Schmidt, Undark | 09.25.2026
In 2010, scientists at the University of Tokyo and other institutions reported a startling achievement: They had successfully grown a pancreas made almost entirely of rat cells within the bodies of mice. The research was directed by Hiromitsu Nakauchi, a...
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...